A Study of CRD3874-SI in People With Leukemia
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether CRD3874-SI is a safe treatment for participants with acute myeloid leukemia (AML).
Eligibility criteria
Qualifiers
Documentation of Disease
Participant must be ≥ 18 years of age at the time of signing the informed consent form (ICF).
Participant must weigh at least 40 kg
Participant has an Eastern Cooperative Oncology Group (ECOG) performance status score 0-2 (See Appendix I for performance status criteria)
Disqualifiers
Participants with acute promyelocytic leukemia
Participants with isolated myeloid sarcoma
Blast phase of chronic myeloid leukemia
Known active central nervous system leukemia
Trial design
Treatments tested in this trial
- CRD3874-SI
Treatment groups
24 Participants
are divided into 3 treatment groupsLocations
7Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)07920, Basking RidgeNew Jersey, United States
Memorial Sloan Kettering Monmouth (All protocol activities)07748, MiddletownNew Jersey, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)07645, MontvaleNew Jersey, United States
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)11725, CommackNew York, United States
Sponsors and collaborators
Memorial Sloan Kettering Cancer Center
Lead sponsor
Source ClinicalTrials.gov